CD274 and urinary bladder carcinoma: Immune checkpoint inhibitors targeting PD‐1/PD‐L1 have revolutionized metastatic bladder cancer treatment by blocking inhibitory signals that suppress T‐cell activity, enabling immune‐mediated tumor destruction [68, 69, 70].